TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency
Phase of Trial: Phase II
Latest Information Update: 16 Sep 2017
At a glance
- Drugs Rucaparib (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms TRITON2
- Sponsors Clovis Oncology
- 08 Sep 2017 Trial design of two studies (TRITON2 and TRITON3) presented at the 42nd European Society for Medical Oncology Congress.
- 30 Aug 2017 According to a Clovis Oncology media release, trial design the study will be presented at European Society for Medical Oncology 2017.
- 10 Jun 2017 Biomarkers information updated